# A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

> **NCT07228390** · PHASE2 · RECRUITING · sponsor: **Pfizer** · enrollment: 240 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Ritlecitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07228390
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-13
- **Primary completion:** 2027-03-05
- **Final completion:** 2027-04-02
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228390, "A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07228390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*